Skip to Main Content
Contribute Try STAT+ Today

Right now, more than 100,000 Americans are waiting for organ transplants. Due to a lack of available kidneys, livers, hearts, and lungs, at least 17 of them die each day.

Using 3D bioprinting to create new organs — and personalize them for recipients — could prevent these tragic deaths. Yet inaction at the Food and Drug Administration is impeding the rollout of this technology. Regulators have not yet come up with a framework for reviewing and approving these lab-grown organs. Until they do, Americans awaiting organ transplants will continue to suffer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment